Company: INDP
Filing Date: 2025-11-12
Form Type: 10-Q
Source: 0001493152-25-021759
Chunk: 21

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-11-12
Form: 10-Q
Item: Part I, Item 1
Chunk 21
---
following table presents reportable segment loss, including significant expenses regularly provided to the CODM, attributable to the
Company’s reportable segment for the periods presented:

 SCHEDULE OF REPORTABLE SEGMENT LOSS 

    2025  
    2024  
    2025  
    2024 

    Three months ended  
    Nine months ended 

    September 30  
    September 30 

    2025  
    2024  
    2025  
    2024 
  
    Research and development: 

    External research and development 
    $1,193,955  
    $839,008  
    $5,197,944  
    $2,543,772 
  
    Internal personnel costs 
     323,768  
     627,029  
     1,297,733  
     2,227,380 
  
    Total research and development 
     1,517,723  
     1,466,037  
     6,495,677  
     4,771,152 
  
    General and administrative 
     1,130,764  
     1,676,020  
     5,182,132  
     6,423,029 
  
    Other income, net 
     (39,088) 
     (73,021) 
     (94,764) 
     (303,201)
  
    Change in fair value of convertible promissory notes 
     365,718  
     -  
     1,153,421  
     - 
  
    Net loss 
    $2,975,117  
    $3,069,036  
    $12,736,466  
    $10,890,980 

NOTE
10: SUBSEQUENT EVENTS

The
Company evaluated subsequent events from September 30, 2025, the date of these unaudited condensed consolidated financial statements,
through November 12, 2025, which represents the date the condensed consolidated financial statements were issued, for events requiring
recognition or disclosure in the condensed consolidated financial statements for the nine months ended September 30, 2025. The Company
concluded that no events have occurred that would require recognition or disclosure in the condensed consolidated financial statements.

F-12

Item
2